Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Nona Biosciences, Boostimmune Enter ADC Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Nona Biosciences, Boostimmune Enter ADC Alliance

To leverage Nona's Harbour Mice H2L2 platform to accelerate development of Antibody-Drug Conjugates against novel targets.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd. committed to technology innovations and providing a total solution from “Idea to IND” (“I to ITM”), has entered into a collaboration agreement with Boostimmune, a biotech company developing next-generation anti-cancer therapies via modulating immune systems. The collaboration aims to leverage Nona’s Harbour Mice H2L2 (two light and two heavy chain) platform to accelerate the development of Antibody-Drug Conjugates (ADCs) against novel targets.
 
Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, said, “By leveraging our accumulated knowledge of ADC discovery and utilizing our advanced therapeutic antibody platforms validated by partners worldwide, this collaboration will expedite the development of first-in-class ADCs targeting cancer. Working alongside Boostimmune, we anticipate delivering transformative treatments, ultimately improving outcomes for all patients affected by cancer.”
 
Gwanghee Lee, Founder and CEO of Boostimmune, said, “We are excited to collaborate with Nona Biosciences. Our strategic alignment of resources and knowledge will accelerate the development of ADC therapies against novel targets. Through this collaboration, we are confident in making significant strides in addressing the unmet needs of cancer patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics